Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP0533 monotherapy in relapsed or refractory AML and MDS/AML
NL-OMON59141Phase 2Completed
- Sponsor
- Molecular Partners AG
- Start
- Mar 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MP0533 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Molecular Partners AG. Primary endpoints: Incidence of CRS and non-CRS dose-limiting toxicities, Adverse events and 2 more. Started Mar 2023; status: completed.
02
Drugs
MP0533
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON59141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59141.